ANACETRAPIB - Watsons Health


Anacetrapib is a CETP inhibitor being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.

Anacetrapib reduces the transfer of cholesteryl ester from HDL to LDL and/or VLDL thereby, producing an increase in serum HDL-cholesterol levels and a decrease in serum LDL-cholesterol levels.

The large morbidity and mortality trial with anacetrapib, known as REVEAL and run by researchers at the University of Oxford, is currently ongoing, and full results are expected in 2017.

There is not enough information about the side effects of this drug. However, since it contains inactive ingredients, allergic reaction may be triggered.


The use of this drug has not approved yet due to insufficient data. There is an on-going research about this drug.



Research is still on-going there is no full result about it yet.

Data hasn’t proved yet that increasing HDL (or too much intake of this drug) is bad for someone’s health. Research about this is still on going.

Related Articles


Drotaverine is an antispasmodic medication that works through the interference of phosphodiesterase-IV which has a fast and specific action on [...]


Droperidol is a dopamine inhibitor which suspends the chemical receptor’s simulation in the postrema region. It has a vasodilator property [...]


Ustekinumab, a human monoclonal antibody that attaches to and blocks interleukins (IL)-12 and IL-23 cytokines. These interleukins (IL)-12 and IL-23 [...]